Bausch + Lomb Misses 24-Hour Target in BL1332 Study for Post-Surgical Eye Pain
Key Facts
Bausch + Lomb announced results on November 19 from the Phase 2 study of BL1332, a topical candidate for ocular surface pain after myopia-correction surgery, and said the study did not meet its primary endpoint during the first 24 hours after surgery. The trial included 129 adults who underwent photorefractive keratectomy (PRK) in one eye and randomly assigned them in a 2:2:1 ratio to BL1332 concentrations of 0.30% and 0.15%, or placebo. The endpoint measured the sum of pain-intensity differences over 24 hours, known as SPID. The least-squares mean difference versus vehicle was -11.5 with the 0.30% concentration and -9.0 with the 0.15% concentration, negative values reflecting a numerical trend in favor of treatment. But they were not enough to establish a statistically significant improvement in the primary comparison, leaving the trial's main endpoint unmet.
The dosing regimen called for five administrations during waking hours over 24 hours for three days after surgery, and the study followed participants through Day 14. This meant the assessment combined a pain measurement on the first day with observation of outcomes during the subsequent short recovery period. In a secondary analysis, the company said the 0.30% concentration achieved a nominally significant reduction in pain during the first six hours. Exploratory analyses of total SPID also showed numerical improvement with both concentrations through 72 hours after surgery. These remain additional indicators within the study; they do not change the failure to meet the primary endpoint defined for the 24-hour period.
In an exploratory analysis six hours after surgery, complete pain resolution was reported by 14.0% of patients who received the 0.30% concentration and 14.6% of those who received the 0.15% concentration. The rate was 3.7% in the placebo group at the same time point. This comparison shows the share of patients who said their pain had resolved completely, alongside pain-intensity analyses covering longer periods. The company did not report statistical significance for these rates in its announced results, so they remain an exploratory finding. The difference between groups shows an early signal in favor of both doses on this measure, without determining the outcome of the primary study.
Optical coherence tomography of the anterior segment of the eye, conducted in a subset of participants, found greater central corneal epithelial thickness on Day 3 among users of both concentrations than among placebo recipients. The company considered this finding consistent with faster healing of the corneal surface. The measurement came in the context of a study testing treatment after PRK, in which monitoring pain and recovery in the days after surgery formed part of the assessment. However, the result was reported in a subgroup analysis, not as the primary endpoint. Overall follow-up extended through Day 14, after dosing over the first three days.
On safety, treatment-emergent adverse events were recorded in 6.0% of recipients of the 0.30% concentration, 13.7% of recipients of the 0.15% concentration and 14.8% of the placebo group. There were no serious adverse events or treatment-related events, and no participant discontinued treatment because of an adverse event. These rates provide a direct comparison among the dose and vehicle groups in the Phase 2 study. The rate of recorded events in the 0.30% concentration group was lower than the rates in the other two groups, while the rate for 0.15% was between them. The company announced these results alongside the pain and corneal-healing findings.
BL1332 was listed in the company's 2026 program as a candidate for a Phase 2 study, with initial results expected in the second half of the year. Before the current study, a Phase 1b exploratory trial showed complete pain resolution in 68.2% of eyes treated with BL1332, compared with 0% of placebo eyes, and the average duration of pain was 1.6 seconds versus 37.8 seconds after a capsaicin challenge. These figures come from an earlier study and differ from the assessment of pain after PRK surgery in Phase 2. Following the results announcement, the U.S.-listed company's shares fell about 4% in extended trading, according to Reuters. Bausch + Lomb is completing analysis of the full data set and expects to discuss the results with the U.S. Food and Drug Administration to assess study design, endpoints and patient groups, including potential Phase 3 planning.